within Pharmacolibrary.Drugs.ATC.D;

model D05AX07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.025,
    Cl             = 14.2 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,
    adminCount     = 1,
    Vd             = 0.391,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Tapinarof is an aryl hydrocarbon receptor (AhR) agonist indicated for the topical treatment of plaque psoriasis in adults. It is a non-steroidal, small-molecule therapeutic, and is currently approved for use as a topical cream.</p><h4>Pharmacokinetics</h4><p>Reported in healthy adult subjects after topical administration.</p><h4>References</h4><ol><li><p>Bissonnette, R, et al., &amp; Armstrong, A (2021). Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. <i>Journal of the American Academy of Dermatology</i> 84(4) 1059–1067. DOI:<a href=&quot;https://doi.org/10.1016/j.jaad.2020.10.085&quot;>10.1016/j.jaad.2020.10.085</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33157177/&quot;>https://pubmed.ncbi.nlm.nih.gov/33157177</a></p></li><li><p>Silverberg, JI, et al., &amp; McHale, KA (2024). Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: A clinical review. <i>The Journal of allergy and clinical immunology</i> 154(1) 1–10. DOI:<a href=&quot;https://doi.org/10.1016/j.jaci.2023.12.013&quot;>10.1016/j.jaci.2023.12.013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38154665/&quot;>https://pubmed.ncbi.nlm.nih.gov/38154665</a></p></li><li><p>Lo, A, et al., &amp; Feldman, SR (2024). Clinical pharmacokinetics and pharmacodynamics of topical non-biological therapies for psoriasis patients. <i>Expert opinion on drug metabolism &amp; toxicology</i> 20(4) 235–248. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2024.2337749&quot;>10.1080/17425255.2024.2337749</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38553411/&quot;>https://pubmed.ncbi.nlm.nih.gov/38553411</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D05AX07;
